文献速递头颈部肿瘤放疗

IMRT时代局部晚期鼻咽癌同步放化疗联合或不联合辅助化疗的十年生存结局:按高危和低危分层的回顾性队列研究

Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-06-27

该回顾性队列研究纳入2009-2012年477例非转移性鼻咽癌患者,比较同步放化疗联合辅助化疗(n=315)与单纯同步放化疗(n=162)的10年生存结局。结果显示联合辅助化疗未显著改善总生存、无局部区域失败生存、无远处转移生存或无失败生存,且低危患者中辅助化疗与总生存和无失败生存降低相关。

要点

  • 联合辅助化疗未显著改善局部晚期鼻咽癌的10年OS、LFFS、DMFS和FFS。
  • 高危患者中辅助化疗未显著改善OS或其他生存终点。
  • 低危患者中辅助化疗与OS和FFS降低相关,LFFS和DMFS无获益。

核心结论

  • 在IMRT时代局部晚期鼻咽癌中,同步放化疗后加用辅助化疗未改善10年生存结局。
  • 辅助化疗可能对低危患者生存产生不利影响,提示需要风险 Adapted 治疗策略。

研究设计与样本

  • 回顾性队列研究,分析2009-2012年477例非转移性鼻咽癌患者。
  • 患者接受同步放化疗联合辅助化疗(n=315)或单纯同步放化疗(n=162)。
  • 采用已发表的预后模型进行高危/低危分层。
  • 采用Kaplan-Meier法比较10年总生存、无局部区域失败生存、无远处转移生存和无失败生存。

主要发现

  • 整个队列的10年OS、DMFS、LFFS和FFS分别为71.7%、81.4%、87.9%和68.1%。
  • 与单纯同步放化疗相比,联合辅助化疗未显著改善OS(70.9% vs. 73.4%;HR=1.036,95%CI:0.717-1.497,P=0.849)。
  • 联合辅助化疗未显著改善LFFS(87.5% vs. 88.7%;HR=1.176,95%CI:0.642-2.154,P=0.598)、DMFS(79.4% vs. 85.3%;HR=1.356,95%CI:0.839-2.191,P=0.211)或FFS(66.4% vs. 71.5%;HR=1.133,95%CI:0.803-1.599,P=0.477)。
  • 高危患者中,辅助化疗未显著改善OS(62.7% vs. 57.5%;HR=0.755,95%CI:0.511-1.115,P=0.156)或其他生存终点。
  • 低危患者中,辅助化疗与OS降低相关(84.8% vs. 94.1%;HR=3.319,95%CI:0.966-11.401,P=0.043)和FFS降低相关(77.8% vs. 92.0%;HR=2.596,95%CI:1.064-6.332,P=0.029),LFFS和DMFS无获益。

临床怎么用

  • 对于IMRT时代局部晚期鼻咽癌,同步放化疗后常规加用辅助化疗可能不应作为标准推荐。
  • 低危患者应避免辅助化疗,因其可能与生存降低相关。
  • 高危患者辅助化疗的价值仍需进一步研究,当前证据未显示显著获益。

局限性

  • 回顾性队列研究设计,存在选择偏倚可能。
  • 样本量有限,低危患者辅助化疗组的生存降低结果需谨慎解读。
  • 风险分层基于已发表预后模型,可能未涵盖所有预后因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate 10-year survival outcomes of intensity-modulated radiotherapy (IMRT)-era locoregionally advanced nasopharyngeal carcinoma (NPC) treated with concurrent chemoradiotherapy (CCRT) ± adjuvant chemotherapy (AC), and assess the impact of AC on survival in high-risk and low-risk patients. METHODS: This retrospective cohort study analyzed 477 non-metastatic NPC patients (2009-2012) treated with CCRT + AC (n = 315) or CCRT alone (n = 162). Risk stratification into high-/low-risk subgroups utilized a published prognostic model. Kaplan-Meier estimates compared 10-year overall survival (OS), locoregional failure-free survival (LFFS), distant metastasis-free survival (DMFS), and failure-free survival (FFS). RESULTS: The 10-year OS, DMFS, LFFS, and FFS rates for the entire cohort were 71.7 %, 81.4 %, 87.9 %, and 68.1 %, respectively. Compared to CCRT alone, CCRT + AC demonstrated no significant improvement in OS (70.9 % vs. 73.4 %; HR = 1.036, 95 % CI: 0.717-1.497, P = 0.849), LFFS (87.5 % vs. 88.7 %; HR = 1.176, 95 % CI: 0.642-2.154, P = 0.598), DMFS (79.4 % vs. 85.3 %; HR = 1.356, 95 % CI: 0.839-2.191, P = 0.211), or FFS (66.4 % vs. 71.5 %; HR = 1.133, 95 % CI: 0.803-1.599, P = 0.477). In high-risk patients, AC failed to enhance OS (62.7 % vs. 57.5 %; HR = 0.755, 95 % CI: 0.511-1.115, P = 0.156) or other survival endpoints. Notably, AC was associated with reduced OS (84.8 % vs. 94.1 %; HR = 3.319, 95 % CI: 0.966-11.401, P = 0.043) and FFS (77.8 % vs. 92.0 %; HR = 2.596, 95 % CI: 1.064-6.332, P = 0.029) in low-risk patients, while showing no benefit in LFFS or DMFS. CONCLUSION: The addition of AC to CCRT did not improve 10-year survival outcomes in locoregionally advanced NPC. Moreover, AC may adversely impact survival in low-risk patients, highlighting the need for risk-adapted therapeutic strategies.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li WJ, Ling LT, Yao Y, et al. Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles. Clin Transl Radiat Oncol. 2025. PMID: 40673136. doi:10.1016/j.ctro.2025.101006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。